213 related articles for article (PubMed ID: 33092509)
1. Chalcone Derivatives and their Activities against Drug-resistant Cancers: An Overview.
Xiao J; Gao M; Diao Q; Gao F
Curr Top Med Chem; 2021; 21(5):348-362. PubMed ID: 33092509
[TBL] [Abstract][Full Text] [Related]
2. Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship.
Gao F; Huang G; Xiao J
Med Res Rev; 2020 Sep; 40(5):2049-2084. PubMed ID: 32525247
[TBL] [Abstract][Full Text] [Related]
3. Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor.
Cai CY; Zhang W; Wang JQ; Lei ZN; Zhang YK; Wang YJ; Gupta P; Tan CP; Wang B; Chen ZS
Biochem Pharmacol; 2020 May; 175():113848. PubMed ID: 32044354
[TBL] [Abstract][Full Text] [Related]
4. Natural Chalcones and Their Derivatives Target the Tumor Microenvironment in Colon Cancer.
Malla RR; Siragam S; Dadi V; Seetini B
Crit Rev Immunol; 2022; 42(6):27-39. PubMed ID: 37082949
[TBL] [Abstract][Full Text] [Related]
5. Chalcones: Promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer.
WalyEldeen AA; Sabet S; El-Shorbagy HM; Abdelhamid IA; Ibrahim SA
Chem Biol Interact; 2023 Jan; 369():110297. PubMed ID: 36496109
[TBL] [Abstract][Full Text] [Related]
6. Chalcone Derivatives: Role in Anticancer Therapy.
Ouyang Y; Li J; Chen X; Fu X; Sun S; Wu Q
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208562
[TBL] [Abstract][Full Text] [Related]
7. Chalcones and Gastrointestinal Cancers: Experimental Evidence.
Michalkova R; Kello M; Cizmarikova M; Bardelcikova A; Mirossay L; Mojzis J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983038
[TBL] [Abstract][Full Text] [Related]
8. Advances in chalcones with anticancer activities.
Karthikeyan C; Moorthy NS; Ramasamy S; Vanam U; Manivannan E; Karunagaran D; Trivedi P
Recent Pat Anticancer Drug Discov; 2015; 10(1):97-115. PubMed ID: 25138130
[TBL] [Abstract][Full Text] [Related]
9. Chalcones against the hallmarks of cancer: a mini-review.
de Souza PS; Bibá GCC; Melo EDDN; Muzitano MF
Nat Prod Res; 2022 Sep; 36(18):4809-4826. PubMed ID: 34865580
[TBL] [Abstract][Full Text] [Related]
10. Lead optimization of novel quinolone chalcone compounds by a structure-activity relationship (SAR) study to increase efficacy and metabolic stability.
Knockleby J; Djigo AD; Lindamulage IK; Karthikeyan C; Trivedi P; Lee H
Sci Rep; 2021 Nov; 11(1):21576. PubMed ID: 34732782
[TBL] [Abstract][Full Text] [Related]
11. Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway.
Hou G; Yuan X; Li Y; Hou G; Liu X
Invest New Drugs; 2020 Apr; 38(2):329-339. PubMed ID: 31102118
[TBL] [Abstract][Full Text] [Related]
12. Heterocyclic chalcone analogues as potential anticancer agents.
Sharma V; Kumar V; Kumar P
Anticancer Agents Med Chem; 2013 Mar; 13(3):422-32. PubMed ID: 22721390
[TBL] [Abstract][Full Text] [Related]
13. An Indole-Chalcone Inhibits Multidrug-Resistant Cancer Cell Growth by Targeting Microtubules.
Cong H; Zhao X; Castle BT; Pomeroy EJ; Zhou B; Lee J; Wang Y; Bian T; Miao Z; Zhang W; Sham YY; Odde DJ; Eckfeldt CE; Xing C; Zhuang C
Mol Pharm; 2018 Sep; 15(9):3892-3900. PubMed ID: 30048137
[TBL] [Abstract][Full Text] [Related]
14. Current scenario of indole derivatives with potential anti-drug-resistant cancer activity.
Jia Y; Wen X; Gong Y; Wang X
Eur J Med Chem; 2020 Aug; 200():112359. PubMed ID: 32531682
[TBL] [Abstract][Full Text] [Related]
15. Anticancer Activity of Natural and Synthetic Chalcones.
Constantinescu T; Lungu CN
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768736
[TBL] [Abstract][Full Text] [Related]
16. Chalcones with electron-withdrawing and electron-donating substituents: anticancer activity against TRAIL resistant cancer cells, structure-activity relationship analysis and regulation of apoptotic proteins.
Mai CW; Yaeghoobi M; Abd-Rahman N; Kang YB; Pichika MR
Eur J Med Chem; 2014 Apr; 77():378-87. PubMed ID: 24675137
[TBL] [Abstract][Full Text] [Related]
17. Molecular Docking Study, Cytotoxicity, Cell Cycle Arrest and Apoptotic Induction of Novel Chalcones Incorporating Thiadiazolyl Isoquinoline in Cervical Cancer.
Tantawy MA; Sroor FM; Mohamed MF; El-Naggar ME; Saleh FM; Hassaneen HM; Abdelhamid IA
Anticancer Agents Med Chem; 2020; 20(1):70-83. PubMed ID: 31696811
[TBL] [Abstract][Full Text] [Related]
18. Targeting Ovarian Cancer with Chalcone Derivatives: Cytotoxicity and Apoptosis Induction in HGSOC Cells.
Merve Aydin E; Canıtez İS; Colombo E; Princiotto S; Passarella D; Dallavalle S; Christodoulou MS; Durmaz Şahin I
Molecules; 2023 Nov; 28(23):. PubMed ID: 38067507
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of Mannich bases of heterocyclic chalcone analogs as cytotoxic agents.
Reddy MV; Su CR; Chiou WF; Liu YN; Chen RY; Bastow KF; Lee KH; Wu TS
Bioorg Med Chem; 2008 Aug; 16(15):7358-70. PubMed ID: 18602831
[TBL] [Abstract][Full Text] [Related]
20. Identification of quinoline-chalcones and heterocyclic chalcone-appended quinolines as broad-spectrum pharmacological agents.
Atukuri D; S V; R S; L V; R P; M M R
Bioorg Chem; 2020 Dec; 105():104419. PubMed ID: 33142228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
